Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...

Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

"While the ESSENCE study did not meet statistical significance on its primary endpoint, we believe the results demonstrated a clear treatment effect, showing clinically meaningful functional outcomes ...

Getting a COVID shot might do more than protect against the virus – it could also help cancer patients live longer. A new ...

Resverlogix Corp. (($TSE:RVX)) announced an update on their ongoing clinical study. Resverlogix Corp. is conducting a Phase II clinical study ...

Patients with cancer who received a covid mRNA vaccine within 100 days of beginning immunotherapy treatment gained ...

Researchers found that lung and skin cancer patients who got COVID-19 vaccines reported significantly increased survival ...

New guidelines from the Infectious Diseases Society of America (IDSA) recommend that adults and children with weakened immune ...

Claims that a study conducted by South Korean researchers “proves” a causal link between COVID-19 vaccines and an increased risk of up to six types of cancer have gone viral in recent days. These ...